- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00492440
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
A Phase I Study of Subcutaneous "CYT 107" (Interleukin-7) in Refractory Metastatic Melanoma or Renal Cell Carcinoma
RATIONALE: Interleukin-7 may stimulate the white blood cells to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the safety of recombinant interleukin-7 (IL-7) in patients with metastatic melanoma or locally advanced or metastatic renal cell carcinoma.
- Confirm the previously documented safety profile of non-glycosylated IL-7 in these patients.
- Determine the safety of higher doses of recombinant IL-7 in these patients.
- Determine the maximum tolerated dose of recombinant IL-7 in these patients.
- Determine the biologically active dose of recombinant IL-7 in these patients.
Secondary
- Determine the pharmacokinetics and pharmacodynamics of recombinant IL-7 in these patients.
- Compare the biological and clinical effects of recombinant IL-7 with non-glycosylated IL-7 in these patients.
- Determine the potential antitumor effect of recombinant IL-7 in these patients.
- Determine the dose and administration schedule of recombinant IL-7 in these patients.
OUTLINE: This is a dose-escalation study. Patients are stratified according to lymphocyte count (normal lymphocyte count [CD4+ T cells > 400/mm^3] vs lymphopenic [CD4+ T cells < 400/mm^3]). Patients are assigned to 1 of 2 treatment groups.
- Group 1 (normal lymphocyte count): Patients receive recombinant interleukin-7 (IL-7) subcutaneously once a week (to determine an active dose) for up to 3 weeks in the absence of disease progression or unacceptable toxicity.
- Group 2 (lymphopenic): Patients receive recombinant IL-7 subcutaneously once a week for up to 3 weeks at one dose level below the active dose determined in group 1.
Cohorts of 3-6 patients from each group receive escalating doses of recombinant IL-7 until the maximum tolerated dose (MTD) is determined. The MTD is the defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 30 additional patients may be treated at the MTD.
Patients undergo blood and bone marrow collection periodically for pharmacokinetic, pharmacodynamic, and immunological studies. Samples are analyzed for the presence of antibodies and proteins via ELISA; CD3, CD4, and CD8 T cell counts, CD127, Ki-67, and Bcl-2 expression in CD4+ and CD8+ T cells, and CD19 B cell counts via flow cytometry; and clonal B cell proliferation via PCR and flow cytometry.
After completion of study treatment, patients are followed at 3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Melanoma
- Metastatic disease
Renal cell carcinoma
- Locally advanced and unresectable disease OR metastatic disease
- Refractory to standard therapy OR ineligible to receive standard therapy
- Measurable or evaluable disease
- Previously received high-dose interleukin-2 OR have a contraindication for this treatment
- No previously untreated or unstable brain metastases
- No splenic metastasis
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 3 months
- Absolute neutrophil count > 1,000/mm^3
- Platelet count > 100,000/mm^3
- PT/PTT ≤ 1.5 times upper limit of normal (ULN)
- Creatinine < 1.5 times ULN
- AST and ALT < 2.5 times ULN
- Conjugated (Direct) bilirubin ≤ 1.25 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
LVEF ≥ 45% by cardiac stress test (e.g., stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test) for patients meeting any of the following criteria:
- History of ECG abnormalities
- Symptoms of cardiac ischemia
- At least 50 years of age and over
- Familial or personal history of heart failure
- Previously treated with antimitotic agents susceptible to trigger heart failure
- FEV_1 > 60% of predicted (for patients with a prolonged smoking history or symptoms of respiratory dysfunction)
- No concurrent cognitive impairment or likelihood of developing cognitive impairment on study therapy
- No concurrent splenomegaly or proliferative hematologic disease
- No documented HIV positivity
No acute hepatitis A or hepatitis B or C
- Positive hepatitis B serology indicative of previous immunization (i.e., HBs Ab positive and HBc Ab negative) allowed
- Positive hepatitis C serology allowed provided HCV RNA load by PCR is negative
Resting blood pressure ≤ 140/90 mm Hg on standard antihypertensive therapy
- Untreated hypertensive patients who received standard antihypertensive therapy allowed provided hypertension is well controlled
- No QTc prolongation ≥ 470 msec
- No prior history of cardiovascular disease, arrhythmias, or significant ECG abnormalities
No active infection requiring systemic treatment and/or hospitalization within the past 28 days
- Patients who have completed therapy or are clinically stable on therapy, in the opinion of the investigator, are eligible
- No history of autoimmune disease
- No history of severe asthma
- No history of medical or psychiatric disease that would preclude study treatment
- No documented cirrhosis or documented acute hepatitis
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 2 weeks since prior systemic corticosteroid therapy
- More than 4 weeks since prior and no other concurrent cytotoxic therapy, immunotherapy, biological agents (i.e., cytokines, growth factors, or monoclonal antibodies), or antitumor vaccines
- More than 7 days since prior hepatotoxic drugs unless medically necessary
- More than 2 days since prior alcohol consumption
- More than 1 day since prior acetaminophen use
- No prior splenectomy
- No prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation
- No concurrent palliative therapy
- No concurrent chemotherapy
No concurrent chronic anticoagulation (i.e., high-dose warfarin or heparin)
- Warfarin dose 1 to 2 mg/day allowed
- No concurrent chronic medications for asthma
- No other concurrent investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CYT107 (r-hIL-7)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety of recombinant interleukin-7 (IL-7)
|
Secondary Outcome Measures
Outcome Measure |
---|
Pharmacokinetics and pharmacodynamics of IL-7
|
Comparison of the biological and clinical effects of recombinant IL-7 with non glycosylated IL-7
|
Potential antitumor effect of recombinant IL-7
|
Dose and administration schedule of recombinant IL-7
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Melanoma
Other Study ID Numbers
- CLI-107-04 (Other Identifier: Cytheris)
- 07-C-0114 (Other Identifier: NCI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Intuitive SurgicalCompleted
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on gene expression analysis
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompleted
-
Renmin Hospital of Wuhan UniversityNot yet recruitingStage III Colorectal CancerChina
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
-
The Christie NHS Foundation TrustUnknownSarcoma | Cervical Cancer | Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Primary Peritoneal Cavity CancerUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruiting